Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 3/20 | 0.34 |
| ▸ | FYN | P06241 | 5/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3344624 | 0.84 | CXCR2 (0.36) | CXCR2 | |
| SCHEMBL3367911 | 0.82 | TSHR (0.42) | CXCR2ALDH1A1 | |
| SCHEMBL2638146 | 0.82 | KDM4E (0.31) | CXCR2KDM4EALDH1A1HPGD | |
| SCHEMBL3335908 | 0.80 | FFAR4 (0.33) | CXCR2 | |
| SCHEMBL3367446 | 0.78 | CXCR2 (0.34) | CXCR2 | |
| SCHEMBL956296 | 0.77 | CXCR2 (0.56) | CXCR2FYNHDAC6 | |
| SCHEMBL3339097 | 0.76 | KDM4E (0.30) | KDM4EALDH1A1HPGD | |
| SCHEMBL3338639 | 0.75 | PDE10A (0.33) | — | |
| SCHEMBL3338299 | 0.75 | CXCR2 (0.52) | CXCR2FYN | |
| SCHEMBL3340932 | 0.75 | PDE4D (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100152205-A1 | CXCR2 INHIBITORS | NOVARTIS AG | 2010-06-17 | — | — | US | disclosed |
| EP-2094697-A1 | 5-SULFANYLMETHYL-PYRAZOLO [1,5-A]PYRIMIDIN-7-OL DERIVATIVES AS CXCR2 ANTAGONISTS | Novartis AG (CH) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008062026-A1 | 5-SULFANYLMETHYL-PYRAZOLO [1,5-A] PYRIMIDIN-7-OL DERIVATIVES AS CXCR2 ANTAGONISTS | NOVARTIS AG (CH) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152205-A1 | CXCR2 INHIBITORS | CXCR2, CXCR1, CXCR3 | CXCR2 1/4885FYN 890/4885HDAC6 857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.